Louise Chen (Scotiabank) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Louise Chen's stock ratings?

About 45% of Louise's ratings were profitable over a one-year hold, with an average return of +6.8% per rating, measured by 13Foresight from historical prices.

Q: How is Louise ranked?

Louise Chen is ranked #2534 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Louise Chen

SCOT

Louise Chen

Scotiabank

Wall Street Analyst

★☆☆☆☆

#2534

on 13Foresight · ranked by our own returns

45%

Success Rate

+6.6%

Average Return

36 of 80 calls profitable · -1099.2% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 45% of Louise Chen's ratings turned a profit when each position was held for 1 year — averaging +6.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

101 Buy 26 Hold 0 Sell

Louise's Stock Coverage 72 ratings · 2026-07-14

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
BMY Bristol-Myers Squibb	Jul 09, 2026	HOLD	Buy +0.2% avg upside 42 analysts	$60.00 1.11% Upside	-0.6%
TEVA Teva Pharmaceutical	Jul 08, 2026	BUY	Buy -9.2% avg upside 39 analysts	$40.00 24.40% Upside	-3.2%
ABBV AbbVie	Jul 07, 2026	BUY	Strong Buy -5.9% avg upside 46 analysts	$280.00 12.93% Upside	-2.6%
VRTX Vertex Pharmaceuticals	Jul 07, 2026	BUY	Strong Buy -8.0% avg upside 61 analysts	$558.00 16.10% Upside	-7.1%
TSE:APTX Apotex Health Corp.	Jul 06, 2026	BUY	Strong Buy +4.0% avg upside 10 analysts	$40.00 6.18% Upside	·
REGN Regeneron	Jul 01, 2026	HOLD	Strong Buy +16.5% avg upside 58 analysts	$770.00 16.21% Upside	+5.0%
MRK Merck & Company	Jun 29, 2026	BUY	Strong Buy +4.3% avg upside 43 analysts	$155.00 24.94% Upside	-6.7%
GILD Gilead Sciences	Jun 25, 2026	BUY	Strong Buy -8.9% avg upside 66 analysts	$177.00 34.61% Upside	+6.1%
PFE Pfizer	Jun 23, 2026	BUY	Buy +37.0% avg upside 45 analysts	$30.00 22.59% Upside	-2.2%
JNJ Johnson & Johnson	Jun 09, 2026	BUY	Strong Buy -13.2% avg upside 36 analysts	$265.00 2.88% Upside	+8.4%
AMGN Amgen	May 01, 2026	BUY	Buy -17.0% avg upside 57 analysts	$385.00 6.85% Upside	+8.5%
LLY Eli Lilly & Co	Apr 28, 2026	BUY	Strong Buy -12.7% avg upside 47 analysts	$1300.00 9.98% Upside	+35.5%
INVA Innoviva	Aug 07, 2025	BUY	Buy +28.6% avg upside 12 analysts	$55.00 147.59% Upside	+21.5%
SRPT Sarepta Therapeutics	Aug 07, 2025	BUY	Buy +216.9% avg upside 49 analysts	$80.00 325.02% Upside	+5.5%
COGT Cogent Biosciences	Aug 06, 2025	BUY	Strong Buy -1.9% avg upside 26 analysts	$17.00 54.60% Downside	+250.9%
ARDX Ardelyx	Aug 05, 2025	BUY	Strong Buy +163.7% avg upside 21 analysts	$15.00 191.77% Upside	+0.2%
ACRS Aclaris Therapeutics	Jul 30, 2025	BUY	Strong Buy +81.6% avg upside 15 analysts	$9.00 63.72% Upside	+263.4%
DYN Dyne Therapeutics	Jul 29, 2025	BUY	Strong Buy +62.5% avg upside 30 analysts	$50.00 111.44% Upside	+164.2%
PTCT PTC Therapeutics	Jul 29, 2025	HOLD	Buy -4.6% avg upside 29 analysts	$55.00 32.40% Downside	+83.2%
PVLA Palvella Therapeutics	Jul 22, 2025	BUY	Strong Buy +14.8% avg upside 27 analysts	$50.00 65.73% Downside	+302.1%
CATX Perspective Therapeutics	Jul 10, 2025	BUY	Strong Buy +267.1% avg upside 22 analysts	$15.00 385.36% Upside	-26.8%
GANX Gain Therapeutics	Jul 09, 2025	BUY	Strong Buy +344.0% avg upside 9 analysts	$12.00 581.73% Upside	+1.1%
ZLAB Zai Lab	Jul 02, 2025	BUY	Strong Buy +197.8% avg upside 13 analysts	$55.00 180.41% Upside	-46.1%
EWTX Edgewise Therapeutics	Jun 27, 2025	HOLD	Strong Buy +8.7% avg upside 14 analysts	$14.00 66.16% Downside	+214.8%
SPRY ARS Pharmaceuticals	May 15, 2025	BUY	Strong Buy +174.7% avg upside 12 analysts	$30.00 287.63% Upside	-39.1%
PCVX Vaxcyte	Jan 28, 2025	HOLD	Strong Buy +75.4% avg upside 15 analysts	—	-44.2%
NVO Novo Nordisk	Jan 28, 2025	HOLD	Buy +135.2% avg upside 26 analysts	—	-27.2%
ONCY Oncolytics Biotech	Jan 03, 2025	HOLD	Strong Buy +673.6% avg upside 12 analysts	—	+2.1%
ANL Adlai Nortye Ltd. Sponsored ADR	Jan 03, 2025	HOLD	Strong Buy +143.4% avg upside 7 analysts	—	-40.0%
LYRA Lyra Therapeutics	Jan 03, 2025	HOLD	Hold +4691.7% avg upside 7 analysts	—	-69.6%
SPRO Spero Therapeutics	Jan 03, 2025	HOLD	Buy +534.8% avg upside 12 analysts	—	+113.6%
PDSB PDS Biotechnology	Jan 03, 2025	HOLD	Strong Buy +1931.0% avg upside 11 analysts	—	-53.7%
SCYX SCYNEXIS	Jan 03, 2025	HOLD	Strong Buy +190.8% avg upside 10 analysts	—	-54.7%
ATOS Atossa Therapeutics	Jan 03, 2025	HOLD	Strong Buy +653.4% avg upside 7 analysts	—	-37.6%
ZVRA Zevra Therapeutics	Jun 10, 2024	BUY	Strong Buy +80.8% avg upside 15 analysts	—	+100.0%
ROIV Roivant Sciences	May 30, 2024	BUY	Strong Buy -7.2% avg upside 17 analysts	—	+5.8%
EOLS Evolus	Jan 16, 2024	BUY	Strong Buy +117.9% avg upside 9 analysts	—	+1.7%
IMVT Immunovant	Oct 16, 2023	BUY	Strong Buy +0.8% avg upside 24 analysts	$45.00 16.26% Upside	-22.7%
MESO Mesoblast	Aug 30, 2023	BUY	Strong Buy +54.6% avg upside 14 analysts	$34.00 109.64% Upside	+135.7%
TXMD TherapeuticsMD	Aug 16, 2023	HOLD	Buy +213.3% avg upside 8 analysts	$5.00 153.81% Upside	-54.6%
CH:BSLN Basilea Pharmaceutica	Aug 15, 2023	BUY	Strong Buy +37.9% avg upside 6 analysts	$73.00 39.06% Upside	·
ARQT Arcutis Biotherapeutics	Aug 08, 2023	BUY	Strong Buy +44.1% avg upside 14 analysts	$50.00 84.29% Upside	-9.0%
EFTR eFFECTOR Therapeutics	Aug 08, 2023	BUY	Strong Buy +22083233.3% avg upside 5 analysts	$250.00 41666566.64% Upside	-99.7%
HCM HUTCHMED	Jul 24, 2023	BUY	Strong Buy +182.2% avg upside 9 analysts	$50.00 348.81% Upside	+38.6%
AMRN Amarin	Jul 18, 2023	BUY	Hold -42.9% avg upside 18 analysts	$5.00 65.99% Downside	-44.8%
NBP NovaBridge Biosciences	Jul 06, 2023	BUY	Strong Buy +1017.2% avg upside 14 analysts	$25.00 1244.02% Upside	·
VYNE VYNE Therapeutics	May 12, 2023	BUY	Strong Buy +1954.4% avg upside 9 analysts	$9.00 1267.90% Upside	-63.1%
CFRXQ ContraFect	Mar 17, 2023	HOLD	Buy +10969999900.0% avg upside 10 analysts	—	·
AVTX Avalo Therapeutics	Feb 13, 2023	HOLD	Strong Buy +178.8% avg upside 20 analysts	—	-99.3%
ZTS Zoetis	Nov 03, 2022	BUY	Buy +67.8% avg upside 22 analysts	$250.00 231.67% Upside	+24.8%
CNTB Connect Biopharma Holdings	Jun 02, 2022	BUY	Strong Buy +190.2% avg upside 12 analysts	$5.00 121.15% Upside	+54.4%
ARDS Aridis Pharmaceuticals	Dec 21, 2021	BUY	Strong Buy +13249900.0% avg upside 5 analysts	$18.00 17999899.91% Upside	-62.9%
RVLPQ RVL Pharmaceuticals	Sep 24, 2021	BUY	Strong Buy +624999900.0% avg upside 6 analysts	$6.00 599999900.03% Upside	-22.9%
JAGX Jaguar Animal Health	Sep 20, 2021	BUY	Strong Buy +108.4% avg upside 5 analysts	$5.00 122.32% Upside	-91.6%
EVFM Evofem Biosciences	May 26, 2020	BUY	Buy +270058.8% avg upside 8 analysts	$15.00 178684.32% Upside	·
DE:MRK Merck KGaA	Apr 29, 2020	BUY	Buy -2.3% avg upside 33 analysts	$93.89 32.38% Downside	·
VTRS Viatris	Mar 25, 2020	HOLD	Buy +41.1% avg upside 21 analysts	$22.00 34.23% Upside	-6.1%
TBPH Theravance Biopharma	Feb 25, 2020	BUY	Buy +9.0% avg upside 18 analysts	$55.00 225.54% Upside	-24.9%
PRGO Perrigo Company	Jan 21, 2020	BUY	Hold +568.8% avg upside 20 analysts	$70.00 588.26% Upside	-26.2%
TSE:BHC Bausch Health Companies	Jan 09, 2020	BUY	Buy +774.6% avg upside 29 analysts	$50.99 641.16% Upside	·
FR:ALCOX Nicox SA	Dec 16, 2019	BUY	Strong Buy +1540.8% avg upside 5 analysts	$12.00 2976.90% Upside	·
ALDX Aldeyra Therapeutics	Oct 22, 2019	BUY	Strong Buy +715.5% avg upside 21 analysts	$33.00 1609.80% Upside	+27.4%
AMRX Amneal Pharmaceuticals	May 09, 2019	BUY	Strong Buy +0.5% avg upside 18 analysts	$35.00 103.69% Upside	-67.8%
OPK Opko Health	Nov 09, 2018	BUY	Strong Buy +433.6% avg upside 12 analysts	$20.00 1526.08% Upside	-52.4%
HRTX Heron Therapeutics	Sep 27, 2018	BUY	Strong Buy +6437.6% avg upside 21 analysts	$50.00 11893.31% Upside	-37.5%
TLPH Talphera	Sep 25, 2018	BUY	Buy +231.5% avg upside 15 analysts	—	-44.8%
NBRVF Nabriva Therapeutics	Jul 24, 2018	BUY	Strong Buy +13374900.0% avg upside 9 analysts	$16.00 15999899.94% Upside	·
XFOR X4 Pharmaceuticals	Jun 28, 2018	BUY	Strong Buy +486.4% avg upside 16 analysts	$26.00 542.06% Upside	-37.5%
JAZZ Jazz Pharmaceuticals	Apr 06, 2017	BUY	Strong Buy -8.0% avg upside 35 analysts	—	-2.6%
ANIP ANI Pharmaceuticals	Apr 05, 2017	BUY	Strong Buy +26.0% avg upside 11 analysts	$80.00 1.30% Downside	+22.9%
XENE Xenon	Sep 26, 2016	BUY	Strong Buy -6.9% avg upside 28 analysts	$20.00 70.55% Downside	·
PAHC Phibro Animal Health	Jun 24, 2015	BUY	Hold +14.2% avg upside 10 analysts	$45.00 36.36% Upside	-47.3%

🔒 67 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Louise Chen — Frequently Asked Questions

How accurate are Louise Chen's stock ratings?

Based on the calls 13Foresight could measure, about 45% of Louise's ratings were profitable over a one-year hold, with an average return of +6.8% per rating, or -1099.1% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Louise ranked on 13Foresight?

Louise Chen is currently ranked #2534 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Louise cover?

Louise most recently has ratings on BMY, TEVA, ABBV, VRTX, TSE:APTX, REGN, MRK, GILD, PFE, JNJ, AMGN, LLY and 60 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!